9th Annual Orphan Drugs and Rare Diseases Conference

9th Annual Orphan Drugs and Rare Diseases Conference is organized by SMi Group Ltd and will be held from Oct 15 - 16, 2019 at Holiday Inn London - Kensington Forum, London, England, United Kingdom.

Who Should Attend:
• CEOs, CSOs, Vice Presidents, Directors, Heads, Principals working in:
• Medical Affairs
• Medical Advisory
• Clinical Operations
• Rare Disease Research
• Patient Advocacy
• Commercial Officer
• Orphan Drug Therapeutics
• Healthcare
• Regulatory Affairs
• Rare Disease Charity Officers

Overview:
The market for rare disease products is continuously growing, expecting to reach $176 billion by 2020, with a CGR of 10.5% just for orphan drugs – this is twice the growth rate of the overall prescription drug market (5.3% CGR from 2014-2020). Explanations for this include the arising interest for pharmaceutical companies, primarily for underlying benefits, including the potential discovery of mechanisms for more common diseases, and the involvement of many smaller biotechnology start up companies who are more focused on rare diseases.
 
Following this, SMi are proud to announce our 9th Annual Orphan Drugs and Rare Diseases conference, aiming to bring together solution providers, biotechnology companies, clinical researchers, regulatory professionals and charity leaders together to discuss possible ways to accelerative orphan drug development and access to rare disease patients, including the introduction of recent technologies and products to help aid the access of orphan drugs.

Benefits of Attending:
• HEAR about the success of orphan drug launches following the heavy involvement of patient advocacy programs
• DISCUSS the potential changes in assessing the development of medicines across Europe
• EXPLORE the future landscape orphan drugs following the market access and reimbursement challenges providers are currently facing.
• GAIN INSIGHT into the various challenges facing orphan drug development

Additional details will be posted as soon as they are available.